At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 289 enrolled
Drug / intervention
LY2605541 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of LY2605541 Compared With Insulin Glargine in the Treatment of Type 2 Diabetes Mellitus
In Brief
A Phase 2 clinical trial evaluating LY2605541 and insulin glargine for Diabetes Mellitus, Type 2. Completed, enrolled 289 participants across 25 sites in 8 countries.
Detailed Summary
Comparison of fasting blood glucose levels in patients with Type 2 diabetes after 12 weeks of treatment with a new basal insulin analog or with insulin glargine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesAustralia, Hungary, Poland, Puerto Rico, Romania, Russia, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2009
Enrollment StartJan 2010
Primary CompletionDec 2010
Study CompletionJan 2011
TodayJul 2026
First PostedDec 9, 2009
Enrollment StartJan 1, 2010
Primary CompletionDec 1, 2010
Study CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 16.6 years ago
Interventions
LY2605541drug
subcutaneous injection of LY2605541 every morning with dose titration based on blood glucose measures for 12 weeks
insulin glarginedrug
subcutaneous injection of insulin glargine every morning with dose titration based on blood glucose measures for 12 weeks